Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Small Cell Lung Carcinoma 7Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Lung Neoplasms 4Head and Neck Neoplasms 4Biliary Tract Neoplasms 4Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma 2Liver Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Bile Duct Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Unresectable Stage III NSCLC 1Triple Negative Breast Neoplasms 1Resectable Biliary Tract Cancer 1Radiation Pneumonitis 1

Interventions

Paclitaxel 6apatinib 4camrelizumab 3S 1 (combination) 2Capecitabine 2130-nm albumin-bound paclitaxel 2vorolanib 1titanium silicide 1spartalizumab 1raltitrexed 1olaparib 1lobaplatin 1durvalumab 1Ramucirumab 1Oxaliplatin 1Gastrectomy 1Docetaxel 1Control Groups 1Cisplatin 1CF regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Gastric Cancer × durvalumab × Clear all
NCT03579784 2024-04-19

Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer

Seoul National University Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡